Assertio Therapeutics, Inc. (NASDAQ:ASRT) will be discussing 2Q20 financial results with the investment community.on 7th August 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.assertiotx.com
Earnings Expectation
Assertio Therapeutics, Inc. is reporting second quarter financial results on Friday 7th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, ASRT is expected to report 2Q20 loss of $ 0.03 per share from revenue of $ 25.33 million.
For the full year, analysts anticipate top line of $ 100.22 million, while looking forward to income of $ 0.11 per share bottom line.
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.
